Search

Your search keyword '"Mizuta, Yuki"' showing total 21 results
Start Over Author "Mizuta, Yuki"
21 results on '"Mizuta, Yuki"'

3. Nitric oxide facilitates the targeting Kupffer cells of a nano-antioxidant for the treatment of NASH

Author

Maeda, Hitoshi, Ishima, Yu, Saruwatari, Junji, Mizuta, Yuki, Minayoshi, Yuki, Ichimizu, Shota, Yanagisawa, Hiroki, Nagasaki, Taisei, Yasuda, Kengo, Oshiro, Shun, Taura, Manabu, McConnell, Matthew J., Oniki, Kentaro, Sonoda, Kayoko, Wakayama, Tomohiko, Kinoshita, Manabu, Shuto, Tsuyoshi, Kai, Hirofumi, Tanaka, Motohiko, Sasaki, Yutaka, Iwakiri, Yasuko, Otagiri, Masaki, Watanabe, Hiroshi, and Maruyama, Toru

Published
2022
Full Text
View/download PDF

6. Encapsulation of an Antioxidant in Redox-Sensitive Self-Assembled Albumin Nanoparticles for the Treatment of Hepatitis

Author

Yasuda, Kengo, primary, Maeda, Hitoshi, additional, Kinoshita, Ryo, additional, Minayoshi, Yuki, additional, Mizuta, Yuki, additional, Nakamura, Yuka, additional, Imoto, Shuhei, additional, Nishi, Koji, additional, Yamasaki, Keishi, additional, Sakuragi, Mina, additional, Nakamura, Teruya, additional, Ikeda-Imafuku, Mayumi, additional, Iwao, Yasunori, additional, Ishima, Yu, additional, Ishida, Tatsuhiro, additional, Iwakiri, Yasuko, additional, Otagiri, Masaki, additional, Watanabe, Hiroshi, additional, and Maruyama, Toru, additional

Published
2023
Full Text
View/download PDF

8. A Mannosylated, PEGylated Albumin as a Drug Delivery System for the Treatment of Cancer Stroma Cells

Author

Mizuta, Yuki, primary, Maeda, Hitoshi, additional, Ishima, Yu, additional, Minayoshi, Yuki, additional, Ichimizu, Shota, additional, Kinoshita, Ryo, additional, Fujita, Issei, additional, Kai, Takuma, additional, Hirata, Kenshiro, additional, Nakamura, Teruya, additional, Saruwatari, Junji, additional, Arima, Hidetoshi, additional, Watanabe, Hiroshi, additional, Otagiri, Masaki, additional, and Maruyama, Toru, additional

Published
2021
Full Text
View/download PDF

13. Development of Kupffer cell targeting type-I interferon for the treatment of hepatitis via inducing anti-inflammatory and immunomodulatory actions

Author

Minayoshi, Yuki, Maeda, Hitoshi, Yanagisawa, Hiroki, Hamasaki, Keisuke, Mizuta, Yuki, Nishida, Kento, Kinoshita, Ryo, Enoki, Yuki, Imafuku, Tadasi, Chuang, Victor Tuan Giam, Koga, Tomoaki, Fujiwara, Yukio, Takeya, Motohiro, Sonoda, Kayoko, Wakayama, Tomohiko, Taguchi, Kazuaki, Ishima, Yu, Ishida, Tatsuhiro, Iwakiri, Yasuko, Tanaka, Motohiko, Sasaki, Yutaka, Watanabe, Hiroshi, Otagiri, Masaki, and Maruyama, Toru

Abstract

Because of its multifaceted anti-inflammatory and immunomodulatory effects, delivering type-I interferon to Kupffer cells has the potential to function as a novel type of therapy for the treatment of various types of hepatitis. We report herein on the preparation of a Kupffer cell targeting type-I interferon, an albumin-IFNα2b fusion protein that contains highly mannosylated N-linked oligosaccharide chains, Man-HSA(D494N)-IFNα2b, attached by combining albumin fusion technology and site-directed mutagenesis. The presence of this unique oligosaccharide permits the protein to be efficiently, rapidly and preferentially distributed to Kupffer cells. Likewise IFNα2b, Man-HSA(D494N)-IFNα2b caused a significant induction in the mRNA levels of IL-10, IL-1Ra, PD-L1 in RAW264.7 cells and mouse isolated Kupffer cells, and these inductions were largely inhibited by blocking the interferon receptor. These data indicate that Man-HSA(D494N)-IFNα2b retained the biological activities of type-I interferon. Man-HSA(D494N)-IFNα2b significantly inhibited liver injury in Concanavalin A (Con-A)-induced hepatitis model mice, and consequently improved their survival rate. Moreover, the post-administration of Man-HSA(D494N)-IFNα2b at 2 h after the Con-A challenge also exerted hepato-protective effects. In conclusion, this proof-of-concept study demonstrates the therapeutic effectiveness and utility of Kupffer cell targeting type-I interferon against hepatitis via its anti-inflammatory and immunomodulatory actions.

Published
2019
Full Text
View/download PDF

14. Repeated Administration of Kupffer Cells-Targeting Nanoantioxidant Ameliorates Liver Fibrosis in an Experimental Mouse Model

Author

Maeda, Hitoshi, primary, Minayoshi, Yuki, additional, Ichimizu, Shota, additional, Mizuta, Yuki, additional, Nagasaki, Taisei, additional, Matsusaka, Kotaro, additional, Oshiro, Shun, additional, Oniki, Kentaro, additional, Saruwatari, Junji, additional, Ishima, Yu, additional, Watanabe, Hiroshi, additional, Otagiri, Masaki, additional, and Maruyama, Toru, additional

Published
2020
Full Text
View/download PDF

16. Rehabilitation Risk Management Strategies in Relation to Prescribed Medications

Author

NANBA, Yoshifumi, primary, HIROTSU, Takaaki, additional, HIDANI, Arisa, additional, TANAKA, Minoru, additional, FUJIE, Ryousuke, additional, INATA, Natsumi, additional, MATSUURA, Akihiro, additional, NAKASO, Naoyuki, additional, KONDO, Yoshihiro, additional, MATSUURA, Yuji, additional, ITAGAKI, Yousuke, additional, NAGASE, Takahiro, additional, and MIZUTA, Yuki, additional

Published
2019
Full Text
View/download PDF

17. Development of Kupffer cell targeting type-I interferon for the treatment of hepatitis via inducing anti-inflammatory and immunomodulatory actions

Author

Minayoshi, Yuki, primary, Maeda, Hitoshi, additional, Yanagisawa, Hiroki, additional, Hamasaki, Keisuke, additional, Mizuta, Yuki, additional, Nishida, Kento, additional, Kinoshita, Ryo, additional, Enoki, Yuki, additional, Imafuku, Tadasi, additional, Chuang, Victor Tuan Giam, additional, Koga, Tomoaki, additional, Fujiwara, Yukio, additional, Takeya, Motohiro, additional, Sonoda, Kayoko, additional, Wakayama, Tomohiko, additional, Taguchi, Kazuaki, additional, Ishima, Yu, additional, Ishida, Tatsuhiro, additional, Iwakiri, Yasuko, additional, Tanaka, Motohiko, additional, Sasaki, Yutaka, additional, Watanabe, Hiroshi, additional, Otagiri, Masaki, additional, and Maruyama, Toru, additional

Published
2018
Full Text
View/download PDF

21. [Successful treatment of huge peritoneal metastasis from duodenal gastrointestinal stromal tumor resistant for imatinib mesylate].

Author

Sakakura C, Kumano T, Mizuta Y, Yamaoka N, Sagara Y, Hagiwara A, and Otsuji E

Subjects
Adult, Benzamides, Drug Resistance, Neoplasm, Duodenal Neoplasms drug therapy, Gastrointestinal Stromal Tumors drug therapy, Humans, Imatinib Mesylate, Male, Peritoneal Neoplasms drug therapy, Peritoneal Neoplasms pathology, Tomography, X-Ray Computed, Duodenal Neoplasms pathology, Duodenal Neoplasms surgery, Gastrointestinal Stromal Tumors pathology, Gastrointestinal Stromal Tumors surgery, Peritoneal Neoplasms secondary, Peritoneal Neoplasms surgery, Piperazines therapeutic use, Pyrimidines therapeutic use
Abstract

Constitutive activation of KIT receptor tyrosine kinase is a critical factor in the pathogenesis of gastrointestinal stromal tumors. Imatinib mesylate (IM, Glivec), a selective tyrosine kinase inhibitor, has been shown in clinical studies to work against such tumors. But there is little information on whether combination of IM and surgical treatment can prolong survival in cases with unresectable multiple liver metastases. We report a case of successful treatment of huge peritoneal metastasis from duodenal gastrointestinal stromal tumor resistant for IM. Therefore, we discuss some important implications. This 41-year-old Japanese man underwent a pancreaticoduodenectomy for GIST of the duodenum in January 2003. The postoperative course was good at first, but 3 months after the initial operation, MRI showed multiple liver metastases. The patient was treated with 400 mg of IM once daily with only weak liver dysfunction as a side effect. The initial response to treatment of CR continued for 20 months. Then huge mass of rt. abdomen appeared and gradually increased in size. Examination revealed that this mass is recurrent of peritoneal metastasis of the GIST. Extirpation was performed and this huge mass was recurrent GIST from omentum. Currently, IM is the first-line therapy for non-resectable GISTs, but a single agent therapy often leads to tumor resistance. IM-resistant GIST are treated with combination of novel molecular targeted-drug, RF, TAE, however, the effect is not enough. Surgical treatment is one of the successful treatments of huge peritoneal metastasis from duodenal gastrointestinal stromal tumor resistant for IM. Further examination in more cases of recurrent GIST is also necessary to estimate the effectiveness of treatment with IM.

Published
2007

Catalog

Books, media, physical & digital resources
See catalog results